Clinical landscape of LAG-3-targeted therapy.
LAG-3
cancer treatment
immune checkpoint
immunotherapy
targeted therapy
Journal
Immuno-oncology technology
ISSN: 2590-0188
Titre abrégé: Immunooncol Technol
Pays: England
ID NLM: 9918281581106676
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation immune checkpoint of clinical importance, right next to programmed cell death protein 1 (PD-1) and cytotoxic T-cell lymphocyte antigen-4 (CTLA-4). Indeed, it is the third inhibitory receptor to be exploited in human anticancer immunotherapies. Several LAG-3-antagonistic immunotherapies are being evaluated at various stages of preclinical and clinical development. In addition, combination therapies blocking LAG-3 together with other immune checkpoints are also being evaluated at preclinical and clinical levels. Indeed, the co-blockade of LAG-3 with PD-1 is demonstrating encouraging results. A new generation of bispecific PD-1/LAG-3-blocking agents have also shown strong capacities to specifically target PD-1+ LAG-3+ highly dysfunctional T cells and enhance their proliferation and effector activities. Here we identify and classify preclinical and clinical trials conducted involving LAG-3 as a target through an extensive bibliographic research. The current understanding of LAG-3 clinical applications is summarized, and most of the publically available data up to date regarding LAG-3-targeted therapy preclinical and clinical research and development are reviewed and discussed.
Identifiants
pubmed: 35755891
doi: 10.1016/j.iotech.2022.100079
pii: S2590-0188(22)00010-7
pmc: PMC9216443
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100079Informations de copyright
© 2022 The Author(s).
Références
EMBO Mol Med. 2021 Sep 7;13(9):e14745
pubmed: 34309222
PLoS One. 2017 Sep 21;12(9):e0185169
pubmed: 28934318
J Immunol. 2007 Sep 15;179(6):4202-11
pubmed: 17785860
J Transl Med. 2010 Jul 23;8:71
pubmed: 20653948
ESMO Open. 2019 Mar 12;4(2):e000482
pubmed: 31231559
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
N Engl J Med. 2022 Jan 6;386(1):24-34
pubmed: 34986285
EMBO Mol Med. 2020 Sep 7;12(9):e12706
pubmed: 32648370
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5744-9
pubmed: 9159144
Mol Cancer Ther. 2019 Nov;18(11):2051-2062
pubmed: 31395688
Braz J Med Biol Res. 2017 Mar 23;50(4):e5356
pubmed: 28355349
Expert Opin Ther Targets. 2011 Jan;15(1):91-101
pubmed: 21142803
Front Pharmacol. 2020 Apr 07;11:441
pubmed: 32317979
Blood. 2003 Sep 15;102(6):2130-7
pubmed: 12775570
Invest New Drugs. 2013 Jun;31(3):707-13
pubmed: 22864469
Eur J Immunol. 2001 Oct;31(10):2885-91
pubmed: 11592063
Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20455-60
pubmed: 22158898
Eur J Immunol. 1995 Sep;25(9):2718-21
pubmed: 7589152
JAMA Oncol. 2020 May 1;6(5):676-684
pubmed: 32053137
Eur J Immunol. 1994 Dec;24(12):3216-21
pubmed: 7805750
Oncoimmunology. 2021 Jun 24;10(1):1943180
pubmed: 34239776
Clin Cancer Res. 2019 Aug 1;25(15):4663-4673
pubmed: 31053602
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Clin Cancer Res. 2009 Oct 1;15(19):6225-31
pubmed: 19755389
Eur J Immunol. 1999 Dec;29(12):3867-76
pubmed: 10601994
Front Immunol. 2020 Jul 14;11:1469
pubmed: 32760400
Future Oncol. 2019 Jun;15(17):1963-1973
pubmed: 30977393
J Immune Based Ther Vaccines. 2007 Mar 29;5:5
pubmed: 17394654
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8
pubmed: 24706856
J Immunol. 1998 Oct 15;161(8):4058-65
pubmed: 9780176
Br J Cancer. 2022 May;126(8):1168-1177
pubmed: 34969998
Eur J Immunol. 1996 May;26(5):1180-6
pubmed: 8647185
Methods Mol Biol. 2020;2055:23-60
pubmed: 31502146
Cancer Res. 2014 Jul 1;74(13):3418-28
pubmed: 24769443
Cancer Lett. 2006 Apr 8;235(1):147-53
pubmed: 15946792
Future Oncol. 2021 Apr;17(10):1155-1164
pubmed: 33263418
J Immunother Cancer. 2015 Jan 20;3(1):2
pubmed: 25614821
J Breast Cancer. 2018 Jun;21(2):124-133
pubmed: 29963107
J Immunol. 2000 Jun 1;164(11):5583-9
pubmed: 10820232
J Immunother Cancer. 2019 Feb 13;7(1):46
pubmed: 30760319
Methods. 2019 Feb 1;154:60-69
pubmed: 30208333
Int J Mol Sci. 2021 May 17;22(10):
pubmed: 34067904
Neurosurgery. 2019 Apr 1;84(4):945-953
pubmed: 30189044
Cancer Res. 2003 May 15;63(10):2518-25
pubmed: 12750275
Clin Cancer Res. 2020 Jul 1;26(13):3333-3344
pubmed: 32299814
Oncotarget. 2015 Mar 10;6(7):4936-52
pubmed: 25669973
Clin Cancer Res. 2016 Mar 15;22(6):1330-40
pubmed: 26500235
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
Cancers (Basel). 2021 Apr 27;13(9):
pubmed: 33925565
J Biol Chem. 2019 Apr 12;294(15):6017-6026
pubmed: 30760527
Front Immunol. 2020 Nov 30;11:586907
pubmed: 33329566
J Immunol. 2008 Mar 15;180(6):3782-8
pubmed: 18322184
Cancer Res. 2006 Apr 15;66(8):4450-60
pubmed: 16618772
J Immunol. 2002 Apr 15;168(8):3874-80
pubmed: 11937541
Vaccine. 2020 Apr 9;38(17):3369-3377
pubmed: 32088020
Eur J Immunol. 2002 Jun;32(6):1605-13
pubmed: 12115643
Immunity. 2018 Jul 17;49(1):120-133.e9
pubmed: 30005826
MAbs. 2016;8(3):617-52
pubmed: 26909869
J Vis Exp. 2015 Feb 12;(96):
pubmed: 25741890
Mol Cancer Ther. 2019 Mar;18(3):632-641
pubmed: 30587557
J Biol Chem. 2013 Jul 5;288(27):19861-9
pubmed: 23689374
Front Immunol. 2018 Feb 27;9:385
pubmed: 29535740
Oncotarget. 2017 Feb 28;8(9):15242-15251
pubmed: 28146425
J Immunol Methods. 2018 May;456:7-14
pubmed: 29427592
EMBO Mol Med. 2019 Jul;11(7):e10293
pubmed: 31273938
J Immunol. 2002 Nov 15;169(10):5392-5
pubmed: 12421911
Vaccine. 2006 Jun 29;24(26):5426-33
pubmed: 16621192
Oncotarget. 2017 Jun 27;8(26):41932-41946
pubmed: 28410210
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Eur J Immunol. 2003 Apr;33(4):970-9
pubmed: 12672063
Vaccine. 2007 Jun 11;25(24):4641-50
pubmed: 17493710
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52
pubmed: 24706858
J Transl Med. 2014 Apr 12;12:97
pubmed: 24726012
Clin Pharmacol Ther. 2021 May;109(5):1293-1303
pubmed: 33113155